Abstract
Background Investigation of the effect of SARS-CoV-2 variants and COVID-19 vaccination on inflammatory and immune response to SARS-CoV-2 infection is limited in South Asia.
Objectives We aimed to examine the impact of COVID-19 vaccination and waves of COVID- 19 on inflammatory and immunological biomarkers among COVID-19 patients in India.
Methods This cross-sectional analysis used baseline data from a randomized controlled trial of vitamin D and zinc during COVID-19 infection in India (N=181). Blood samples and data regarding vaccination doses were collected. The second (Delta) or third (Omicron) wave was determined by date of enrolment. Mixed effects linear regression with robust standard errors was used to examine associations between COVID-19 vaccination dose or wave at enrolment and C-Reactive Protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, interleukin-6 (IL-6), angiopoietin-2 (Ang-2), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), immunoglobulin G (IgG) and immunoglobulin M (IgM).
Results Compared to no vaccination, full vaccination was associated with lower LDH (P<0.001), D-dimer (P=0.521) and Ang-2 (P=0.046), and higher IgG levels (P<0.001). Partial vaccination was associated with lower IL-6 (P=0.040) and higher IgG (P<0.001). Enrolment during the third wave was associated with lower IL-6 (P<0.001), CRP (P=0.056), IgM (P=0.013), and IgG (P<0.001), but higher D-dimer levels (P<0.001).
Conclusions COVID-19 vaccination status and SARS-CoV-2 variant influence the inflammatory and immunologic response during SARS-CoV-2 infection, contributing to the severity of clinical presentation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04641195; CTRI/2021/04/032593
Clinical Protocols
https://bmjopen.bmj.com/content/12/8/e061301.abstract
Funding Statement
The collection of baseline data was done under a randomized control trial that was supported by the Canadian Institutes of Health Research, Operating Grant: COVID-19 Rapid Research Funding OpportunityTherapeutics (application number: 447092), and the Canada Research Chair program (to KCK). The funding bodies had no role in study design and procedures, or the decision to submit manuscripts for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The procedures followed in this study were in accordance with the ethical standards of all responsible ethical committees listed below, and with the Declaration of Helsinki, and informed written consent was taken from study participants. Ethical approval was obtained from the Institutional Review Board of the Harvard T.H. Chan School of Public Health (Protocol No. IRB20-1425), the University Health Network Research Ethics Board (20-5775), the Institutional Research Ethics Committee of the Foundation for Medical Research (IREC No. FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No. EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No. 2027). The trial is registered on ClincialTrials.gov: NCT04641195, and Clinical Trial Registry of India (CTRI): CTRI/2021/04/032593. Health Ministry Steering Committee (HSMC) - GOI endorsement was received before the commencement of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.